Abstract | BACKGROUND:
SKI-2053R (SK Chemicals, Kyungki-Do, South Korea) is a new platinum derivative with antitumor activity against various cell lines, including cisplatin-resistant tumor cell lines. Preclinical studies have suggested that it is less nephrotoxic than cisplatin. This study evaluated the efficacy and toxicity of SKI-2053R in the treatment of patients with advanced gastric adenocarcinoma. METHODS: Thirty-seven patients with advanced gastric adenocarcinoma that was unresectable or metastatic were treated. No prior chemotherapy or radiotherapy was allowed. Patients received SKI-2053R 360 mg/m(2) by 1-hour infusion on Day 1. After the first cycle, subsequent doses were adjusted according to the toxicity. Courses were repeated every 28 days. RESULTS: Thirty-five patients were evaluable for response and toxicity. Six patients achieved a major response (17%; 95% confidence interval, 8-33%); 2 were complete and 4 were partial responses. The median duration of response was 7.2 months, with a range of 1-20 months. Patients could tolerate the treatment without significant toxicity. No patients had Grade 3 or 4 toxicity. The most frequent toxicity was Grade 1 or 2 proteinuria (26% of cycles), but it was mild and transient. Leukopenia, thrombocytopenia, azotemia, nausea and vomiting, and neurotoxicity were not frequent. These low toxicity profiles indicated that the dose of SKI-2053R could be increased in future studies. CONCLUSIONS:
|
Authors | N K Kim, S A Im, D W Kim, M H Lee, C W Jung, E K Cho, J T Lee, J S Ahn, D S Heo, Y J Bang |
Journal | Cancer
(Cancer)
Vol. 86
Issue 7
Pg. 1109-15
(Oct 01 1999)
ISSN: 0008-543X [Print] United States |
PMID | 10506693
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 1999 American Cancer Society. |
Chemical References |
- Antineoplastic Agents
- Malonates
- Organoplatinum Compounds
- SKI 2053R
|
Topics |
- Adenocarcinoma
(drug therapy)
- Adult
- Aged
- Antineoplastic Agents
(administration & dosage, therapeutic use, toxicity)
- Female
- Humans
- Male
- Malonates
(administration & dosage, therapeutic use, toxicity)
- Middle Aged
- Organoplatinum Compounds
(administration & dosage, therapeutic use, toxicity)
- Stomach Neoplasms
(drug therapy)
|